Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas

BACKGROUND: ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC. The purpose of this study was to elucidate the underlying molecular mechanism of this interaction and the be...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res
Hlavní autoři: Zoi, Ilianna, Karamouzis, Michalis V., Xingi, Evangelia, Sarantis, Panagiotis, Thomaidou, Dimitra, Lembessis, Panayiotis, Theocharis, Stamatios, Papavassiliou, Athanasios G.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6892243/
https://ncbi.nlm.nih.gov/pubmed/31796128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1226-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky